Belsomra (Suvorexant) for Women: How It Works, Dosing, and Safety

Import from '@/components'

Does Suvorexant (Belsomra) Come as an Injection?

No. Suvorexant is an oral tablet only. There is no injectable, sublingual, patch, or any other formulation of this drug. If you have seen a reference to "Belsomra self-injection technique," it is a content error or a confusion with a different medication. Merck manufactures suvorexant exclusively as a tablet in four strengths: 5 mg, 10 mg, 15 mg, and 20 mg.

This article corrects that confusion directly, then gives you the complete clinical picture you actually need: how the drug works, why women's hormones matter for its effects, which life stages it fits best, and what you must know before taking it if you are pregnant, breastfeeding, or trying to conceive.

How Suvorexant Works: The Orexin System Explained

Suvorexant works by blocking orexin receptors in the brain. Orexin (also called hypocretin) is a neuropeptide that promotes and sustains wakefulness. When orexin binds to its two receptors, OX1R and OX2R, your brain stays alert. Suvorexant sits in both receptor sites and prevents that signal from firing.

This mechanism is categorically different from benzodiazepines or Z-drugs (zolpidem, eszopiclone), which amplify the inhibitory neurotransmitter GABA to sedate the whole brain. Suvorexant does not sedate you into sleep. It removes the active neurological brake on sleep. That distinction matters clinically.

The Orexin Wake-Drive Model

Your brain runs two competing systems: a sleep-promoting system (adenosine, melatonin) and a wake-promoting system (orexin, histamine, norepinephrine). In chronic insomnia, the wake-drive system fires too strongly at night. Suvorexant selectively quiets that one system rather than broadly suppressing the central nervous system.

Herring et al. (Lancet Neurology, 2014) randomized 1,021 adults with insomnia to suvorexant 15/20 mg or 30/40 mg versus placebo across three months. Both active doses significantly reduced time to sleep onset and wake after sleep onset compared with placebo, with the lower dose showing a cleaner side-effect profile. The trial recorded fewer complex sleep behaviors (sleepwalking, sleep-driving) than historical rates with Z-drugs, consistent with the mechanism difference.

Dual Versus Single Receptor Antagonism

Suvorexant blocks both OX1R and OX2R, making it a dual orexin receptor antagonist (DORA). Lemborexant (Dayvigo), approved in 2019, is also a DORA. Daridorexant (Quviviq), approved in 2022, is a third DORA with a shorter half-life. Single-receptor antagonists (SORAs) targeting only OX2R are in late-stage trials but not yet approved. Understanding the class helps you ask your clinician specific questions if suvorexant is not tolerated.

Dosing, Timing, and Drug Interactions in Women

The FDA-approved starting dose is 10 mg, taken no more than 30 minutes before bedtime, with at least 7 hours of sleep time remaining. The maximum dose is 20 mg once nightly.

Why Women May Need Lower Doses

Women metabolize suvorexant differently than men. Suvorexant is a CYP3A4 substrate. Women on average have lower CYP3A4 activity during the luteal phase of the menstrual cycle (days 14-28) and significantly altered CYP3A4 function during pregnancy. The FDA label explicitly notes that women may have higher suvorexant plasma concentrations than men at the same dose, which is why next-morning drowsiness (including impaired driving) is more common in women.

A 10 mg starting dose is the right choice for most women. Moving to 20 mg should be a deliberate, supervised step, not a default.

Hormonal Contraceptives and CYP3A4

Oral contraceptives containing ethinyl estradiol can inhibit CYP3A4 modestly, potentially raising suvorexant exposure. No large dedicated pharmacokinetic trial has examined this combination in women specifically. That is an evidence gap. If you are on combined oral contraceptives and feel unusually groggy the morning after suvorexant, mention it to your prescriber; a lower dose or a switch within the DORA class may be warranted.

Concomitant CNS Depressants

Alcohol, opioids, benzodiazepines, and gabapentinoids all add to suvorexant's CNS depressant effect. Women with insomnia sometimes use alcohol as a sleep aid, which is common but counterproductive and dangerous in combination with any sleep medication. The FDA label carries a boxed-adjacent warning about combined CNS depressant use.

Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir) can double or triple suvorexant exposure. Strong CYP3A4 inducers (rifampin, carbamazepine, some anticonvulsants used in women with epilepsy) may render suvorexant ineffective. Always give your prescriber a full medication list.

Suvorexant Across Women's Life Stages

Insomnia is not one condition experienced uniformly across a woman's life. The driver and the best treatment option can shift substantially depending on where you are hormonally.

Reproductive Years (Ages 18-39)

Insomnia in this life stage is often tied to premenstrual syndrome, anxiety, shift work, or a new infant. Suvorexant is an option for chronic insomnia disorder (defined as difficulty sleeping at least 3 nights per week for at least 3 months) in this group, but cognitive behavioral therapy for insomnia (CBT-I) remains the first-line recommendation per AASM guidelines regardless of age. Pharmacotherapy is typically considered when CBT-I is unavailable, insufficient, or declined.

Because suvorexant is a Schedule IV controlled substance, prescribers weigh dependence risk. The orexin mechanism does not produce the classic benzodiazepine withdrawal syndrome, but rebound insomnia on discontinuation can occur.

PCOS and Insomnia

Women with polycystic ovary syndrome (PCOS) have a significantly higher prevalence of sleep disorders than the general population, including obstructive sleep apnea and insomnia. Suvorexant carries a specific caution for patients with compromised respiratory function because orexin also plays a role in respiratory drive. If you have PCOS with suspected sleep apnea, have that diagnosed and treated before starting any sedative-hypnotic, including suvorexant.

Perimenopause (Ages 40-55)

This is where suvorexant is most frequently prescribed for women in clinical practice. Sleep disruption in perimenopause is driven by vasomotor symptoms (hot flashes, night sweats), rising FSH, declining estrogen, and shifts in circadian rhythm. Up to 60% of perimenopausal women report insomnia symptoms, making this life stage the highest-burden window.

Suvorexant addresses the hyperarousal component of insomnia. It does not reduce hot flashes. If vasomotor symptoms are the primary driver of your sleep disruption, hormone therapy (HT) or a non-hormonal agent targeting vasomotor symptoms (such as fezolinetant) addresses the root cause, while suvorexant treats the downstream insomnia. Both can be used together; your clinician should sequence the evaluation to distinguish pure insomnia from vasomotor-driven sleep disruption, because the first-line treatment differs.

The Menopause Society (formerly NAMS) 2023 position statement on nonhormonal management of menopause acknowledges orexin antagonists as a class under evaluation for menopausal sleep disruption, though specific suvorexant recommendations for this population are still emerging.

Postmenopause (Ages 55 and Older)

Older adults are more sensitive to CNS-active drugs due to slower hepatic metabolism, lower body water, and reduced renal clearance of metabolites. The 2023 American Geriatrics Society (AGS) Beers Criteria lists suvorexant as potentially inappropriate in older adults at doses above 10 mg due to increased risk of falls, excessive daytime sedation, and next-day cognitive impairment. For postmenopausal women, the 5 mg or 10 mg dose is the appropriate ceiling in most cases. That lower-dose-first framework for postmenopausal women is a clinical priority that generic insomnia articles rarely address: start at 5 mg if your prescriber is willing, confirm you can still function safely the next morning, and only escalate if needed.

Pregnancy and Lactation Safety

Suvorexant should not be used during pregnancy. This is a required warning, and the reasoning is specific.

Pregnancy Data

Suvorexant is classified as FDA Pregnancy Category C (pre-2015 labeling system still referenced on many pharmacy printouts), meaning animal studies showed fetal harm and no adequate, well-controlled human trials exist. In animal reproduction studies, suvorexant was associated with developmental toxicity at exposures exceeding those in humans. The FDA prescribing information states that suvorexant should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Given that chronic insomnia has behavioral and non-pharmacological treatment options (CBT-I, sleep hygiene, melatonin at low doses), the risk-benefit calculation rarely supports suvorexant use in pregnancy.

If you become pregnant while taking suvorexant, contact your OB or midwife promptly. Do not stop abruptly without guidance if you are at a higher dose, though suvorexant does not carry the severe withdrawal risk of benzodiazepines.

Lactation

Suvorexant transfers into breast milk in animal studies. No human lactation pharmacokinetic studies have been published. The FDA label advises caution, and given the absence of safety data and the theoretical risk of neonatal CNS depression, most clinicians recommend against use while breastfeeding. Postpartum insomnia is extremely common and deserves treatment, but CBT-I and careful use of low-dose melatonin have substantially more safety data in nursing mothers.

Contraception Requirement

Suvorexant is not classified as a teratogen requiring mandatory contraception in the way that some drugs (isotretinoin, valproate) are. You do not need to be on a specific contraceptive program to receive it. Any woman of reproductive age who is not planning a pregnancy should be using reliable contraception while on any sedative-hypnotic, because unexpected pregnancy does occur and the fetal safety data for suvorexant are inadequate.

Who This Is Right For and Who Should Avoid It

Good Candidates

Women who may benefit most from suvorexant:

• Adults with chronic insomnia disorder who have tried CBT-I without sufficient improvement
• Perimenopausal or postmenopausal women whose insomnia has a significant hyperarousal component rather than being purely vasomotor-driven
• Women who experienced concerning complex sleep behaviors (sleepwalking, sleep eating) on Z-drugs and need an alternative
• Women who need to avoid benzodiazepines due to dependence history or drug interactions

Who Should Avoid Suvorexant or Use It with Caution

• Pregnant women (avoid)
• Breastfeeding women (avoid)
• Women with narcolepsy (suvorexant blocks the orexin system that is already deficient in narcolepsy)
• Women with untreated obstructive sleep apnea (respiratory depression risk)
• Women taking strong CYP3A4 inhibitors (ritonavir, clarithromycin, itraconazole)
• Women with severe hepatic impairment, where clearance is substantially reduced
• Postmenopausal women over 65 at fall risk (use 5-10 mg only, with careful next-day assessment)

Comparing Suvorexant to Other Insomnia Options for Women

Women are often handed a prescription without a clear comparison. Here is a direct look at the main alternatives.

| Drug | Class | Key Women's Note | Controlled? | |---|---|---|---| | Suvorexant 10-20 mg | DORA | Higher plasma levels in women; avoid in pregnancy | Yes, Schedule IV | | Lemborexant 5-10 mg | DORA | Shorter half-life than suvorexant; less next-day sedation in some | Yes, Schedule IV | | Zolpidem 5 mg (women's dose) | Z-drug | FDA mandated lower dose for women in 2013; complex sleep behaviors | Yes, Schedule IV | | Eszopiclone 1-2 mg | Z-drug | Unpleasant taste common; teratogenic risk unestablished | Yes, Schedule IV | | Doxepin 3-6 mg | TCA | Only approved hypnotic for sleep maintenance specifically; anticholinergic at higher doses | No | | Melatonin 0.5-3 mg | Supplement | Best evidence for circadian-phase insomnia; postpartum use has limited but reassuring data | No | | CBT-I | Behavioral | First-line per AASM; durable effects; works across all life stages | N/A |

The 2017 AASM clinical practice guideline gives suvorexant a weak recommendation for sleep-onset and sleep-maintenance insomnia, reflecting moderate-quality evidence and the need for more head-to-head trial data against other agents.

Side Effects Women Report Most

Next-day somnolence is the most common side effect reported in Herring et al., occurring in approximately 7% of patients on the 15/20 mg dose versus 3% on placebo. Women report this at higher rates than men due to pharmacokinetic differences described above.

Other notable effects:

• Sleep paralysis and hypnagogic hallucinations. These occur more frequently with DORAs than with Z-drugs because orexin normally suppresses REM intrusion into wakefulness. The incidence is low (under 1% in trials) but alarming when it happens. Reassure yourself that it is transient and not dangerous, and report it to your prescriber.
• Cataplexy-like episodes. Rare, but because orexin deficiency causes narcolepsy-cataplexy, blocking orexin can produce mild cataplexy-like muscle weakness in susceptible individuals.
• Suicidal ideation. The FDA label includes a warning about worsening depression and suicidal ideation, consistent with all sedative-hypnotics. Women have higher rates of both insomnia and depression than men, so this interaction deserves explicit monitoring.

What to Expect in the First 30 Days

You take one tablet 30 minutes before your intended bedtime, with at least 7 hours before you need to be alert. Effects are noticeable within the first few nights for many women, though the full benefit on sleep efficiency accumulates over 4 weeks in clinical trial data.

Do not drive or operate machinery until you know how suvorexant affects your next-morning alertness. The FDA issued a specific driving impairment warning for suvorexant in 2014, and a subsequent Drug Safety Communication in 2018 extends that warning across the sedative-hypnotic class. Test your morning alertness on a weekend or day off before driving to work.

If you are perimenopausal and your sleep disruption is heavily tied to night sweats, track whether suvorexant improves your time-to-sleep but you are still waking drenched. That pattern suggests you need concurrent vasomotor management, not a higher suvorexant dose.

Your prescriber should reassess at 4 weeks. If 10 mg is not effective and side effects are tolerable, a single step to 20 mg is the maximum. No titration above 20 mg exists, and higher doses do not improve efficacy but substantially raise next-day impairment risk.